Calidi Biotherapeutics, Inc. (CLDI) Stock Price & How to Invest
Last updated November 2026
Short answer
You can invest in Calidi Biotherapeutics (CLDI) by buying shares or fractional shares at any major broker, through an ETF that holds it, or as one holding in a thematic basket. Calidi is a preclinical-to-early-clinical immuno-oncology company developing virotherapies that use engineered viruses to attack tumors. Its stated focus in 2026 is the RedTail platform, a systemically delivered, enveloped oncolytic virus whose lead candidate CLD-401 is targeted to dose its first patient in the first quarter of 2027, alongside the earlier stem-cell-loaded programs CLD-101 (NeuroNova) and CLD-201 (SuperNova). The thesis is that shielded, systemically delivered oncolytic viruses could reach metastatic tumors that current virotherapies cannot. The biggest risk is that this is a highly speculative, pre-revenue nano-cap (about $3 million of market value in October 2026) with roughly $4 million of cash, substantial doubt about its ability to continue as a going concern, a 2026 NYSE American listing-deficiency notice, repeated dilution and two reverse stock splits in under a year, and value that hinges almost entirely on early-stage outcomes.
CLDI stock price
As of 2026-11-16, Calidi Biotherapeutics, Inc. (CLDI) last closed at $0.6020, down 97.5% over the past year. Over the past 52 weeks it has traded between $0.6020 and $24.64.
Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or Calidi Biotherapeutics, Inc.'s investor relations page. Walnut is informational, not investment advice.
CLDI key stats
At $0.60 on November 16, 2026, Calidi Biotherapeutics, Inc. (CLDI) has a market cap of $2M.
- Market cap
- $2M
- Price to book
- 0.4
- Beta
- 1.37
Market cap, P/E and yield are measured at the $0.60 price on November 16, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.
What's new with Calidi Biotherapeutics, Inc. (CLDI)?
The last two weeks for Calidi Biotherapeutics, Inc., as of November 17, 2026: the price move, the next earnings date, what the company filed with the SEC, and what analysts changed.
- CLDI closed at $0.60 on November 16, 2026, down 17.9% over the past five trading days (from $0.73).
- On November 13, 2026, Calidi Biotherapeutics, Inc. filed its quarterly report (10-Q) with the SEC. Read the 10-Q on sec.gov
- On November 13, 2026, Calidi Biotherapeutics, Inc. filed an 8-K with the SEC reporting quarterly results and information shared with investors (Regulation FD) (Item 2.02, Item 7.01). Read the 8-K on sec.gov
Prices are daily closes from Yahoo Finance. Filings are read from SEC EDGAR every six hours. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.
What does Calidi Biotherapeutics, Inc. (CLDI) do?
Calidi Biotherapeutics, Inc. is an immuno-oncology company based in San Diego, California, developing therapies that use oncolytic viruses, and in some programs cell-based delivery, to target hard-to-treat cancers. Its founding approach was to shield therapeutic viruses inside stem cells so they can survive the immune system long enough to reach and destroy tumors, and its newer RedTail platform pursues the same goal with an engineered enveloped virus designed for intravenous delivery to metastatic sites. In its August 2026 update the company described RedTail as its lead platform: CLD-401, which carries an IL-15 superagonist payload, is in IND-enabling studies for metastatic non-small cell lung cancer, head and neck cancer and other solid tumors, and after positive pre-IND feedback from the FDA it is targeting first patient dosing in the first quarter of 2027. A second RedTail compound, CLD-501, adds an in situ TROP-2 T-cell engager and was shown preclinically at ASCO 2026. The earlier pipeline includes CLD-101 (NeuroNova), studied in Phase 1 for high-grade glioma, and CLD-201 (SuperNova), an allogeneic stem-cell-loaded viral therapy for solid tumors such as soft tissue sarcoma; the 2026 updates focus on RedTail and say little about those programs. The company generates no product revenue and is years away from any potential approval.
Calidi became publicly traded in 2023 through a merger with a special purpose acquisition company (SPAC) and trades on NYSE American. Earlier milestones include FDA clearance of an investigational new drug application for CLD-201 in April 2025 and Fast Track designation for CLD-201 in soft tissue sarcoma in July 2025. The financial reality is stark and has worsened in 2026. The company reported a net loss of about $25.6 million for 2025, and for the second quarter of 2026 a net loss of $4.2 million ($2.94 per share), with general and administrative costs cut 48% to $1.6 million. Cash fell to about $4.1 million (plus $0.2 million restricted) at June 30, 2026, from $5.6 million at year-end. It effected a 1-for-16 reverse stock split on July 30, 2026, less than a year after a 1-for-12 split in August 2025, raised only about $1.2 million in a September 2026 registered direct offering at $1.17 a share, and in September received an NYSE American notice that its $3.1 million of stockholders' equity is below the $4.0 million continued-listing standard. It has until October 21, 2026 to submit a plan to regain compliance by March 21, 2028. The shares closed at about $0.86 on October 16, 2026, down roughly 95% year to date, for a market value near $3 million.
What's driving Calidi Biotherapeutics, Inc. (CLDI)?
1. Stem-Cell-Shielded Virotherapy Platform.
Calidi's core idea is to load oncolytic viruses inside stem cells so the viruses can evade the patient's immune defenses and reach tumors intact. This addresses a known limitation of conventional virotherapy, where the immune system can neutralize a virus before it acts. If validated in trials, the same delivery concept could in principle extend across multiple cancer types. Platform validation remains unproven in late-stage human studies, so this is a scientific thesis rather than an established result. The 2026 strategy leans more on the enveloped-virus version of that idea (RedTail) than on stem-cell carriers.
2. CLD-201 SuperNova and FDA Designations.
CLD-201 is an allogeneic, off-the-shelf stem-cell-loaded viral therapy aimed at solid tumors including soft tissue sarcoma, triple-negative breast cancer, and head and neck cancer. The FDA cleared its IND in April 2025 and granted Fast Track designation for the sarcoma indication in July 2025, which can mean more frequent FDA interaction and potential eligibility for expedited review. The company's 2026 updates have centered on RedTail rather than on a CLD-201 trial start, so its timing is unclear. These designations support development but do not guarantee that the therapy will prove safe or effective.
3. RedTail and CLD-401, the Lead Program.
RedTail (the RTNova platform) uses an enveloped virotherapy designed for intravenous delivery, which could allow systemic, potentially repeatable dosing to reach metastatic disease rather than only locally injected tumors. Its lead candidate, CLD-401, delivers an IL-15 superagonist into the tumor microenvironment; after a pre-IND meeting in which the FDA agreed on key aspects of manufacturing and non-clinical plans, Calidi is targeting first patient dosing in the first quarter of 2027. CLD-501 adds an in situ TROP-2 T-cell engager and an EpCAM-targeted version is in development. All of this is still preclinical, so it carries high scientific uncertainty, and reaching the clinic depends on financing the company does not yet have.
4. Large Unmet Need in Hard-to-Treat Cancers.
Calidi targets cancers with poor prognoses and limited options, such as high-grade glioma and advanced solid tumors, where a differentiated mechanism could matter if it works. The addressable patient populations are meaningful, and immuno-oncology remains an active area of investment and partnership interest. However, addressing a large unmet need is only valuable if the therapy clears clinical trials and reaches the market, neither of which is assured for an early-stage company with limited resources.
5. Cost Cuts and the Funding Gap.
Calidi cut general and administrative expenses 48% year over year in the second quarter of 2026 and signed a smaller San Diego lease it estimates will save about $1.1 million a year. Those steps slow the burn but do not close the gap: quarterly losses of around $4 million compare with about $4.1 million of cash at June 30, 2026 and a September raise of only about $1.2 million. Further dilutive financing, a partnership, or a strategic transaction is likely needed to reach a CLD-401 trial.
What are the risks to Calidi Biotherapeutics, Inc. (CLDI)?
Calidi is a pre-revenue, preclinical-to-early-clinical nano-cap whose value depends almost entirely on early-stage outcomes, so a single failure, safety signal, or program delay could sharply reduce the stock. The company has reported substantial doubt about its ability to continue as a going concern, held only about $4.1 million in cash at June 30, 2026 against quarterly net losses near $4 million, and funds itself through repeated dilutive equity raises that erode existing shareholders; it also carries a large warrant overhang. It completed a 1-for-12 reverse split in August 2025 and a 1-for-16 reverse split in July 2026, yet the shares still fell to about $0.86 by October 16, 2026, down roughly 95% for the year. In September 2026 NYSE American notified it that stockholders' equity of $3.1 million is below the $4.0 million standard; if its compliance plan (due October 21, 2026) is not accepted, delisting proceedings would begin. There is no product revenue, no profit, and no certainty that any program will ever be approved or commercialized. This is among the most speculative categories of stock, and a total or near-total loss is a realistic outcome.
Is CLDI a buy or a sell?
We give no verdict on Calidi Biotherapeutics, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.
The case for buying. Stem-Cell-Shielded Virotherapy Platform. Calidi's core idea is to load oncolytic viruses inside stem cells so the viruses can evade the patient's immune defenses and reach tumors intact.
The case against. Calidi is a pre-revenue, preclinical-to-early-clinical nano-cap whose value depends almost entirely on early-stage outcomes, so a single failure, safety signal, or program delay could sharply reduce the stock.
Read the full bull and bear case on CLDI, including what would have to change to break either one. Walnut is not an investment adviser.
Has Calidi Biotherapeutics, Inc. (CLDI) split its stock?
Yes. Calidi Biotherapeutics, Inc. (CLDI) has had 3 share splits in the last 10 years:
- 1:10 on July 15, 2024, so every share held became 0.1 shares.
- 1:12 on August 5, 2025, so every share held became 0.08333333333333333 shares.
- 1:16 on July 31, 2026, so every share held became 0.0625 shares.
A split changes the share count and the price per share and leaves the value of a holding unchanged. Someone holding $1,000 of CLDI the day before the 1:16 split held $1,000 the day after, in more shares at a proportionally lower price. Historical prices from before the date are normally shown split-adjusted, which is why a long-run chart shows no cliff.
Splits matter mainly because they make older price figures confusing to compare by hand, and because a board choosing to split is usually signalling that the price has run up far enough to feel awkward for smaller buyers. Neither is a reason to buy or sell.
How is Calidi Biotherapeutics, Inc. (CLDI) valued?
Market cap, P/E and dividend yield at today's price are in the CLDI key stats above. The business figures below come from Calidi Biotherapeutics, Inc.'s reported results as of October 2026 (Q2 2026 results, filings through September 2026) and change when it next reports.
- Revenue: None (no approved products; pre-revenue)
- Net loss (Q2 2026): ~$4.2 million ($2.94 per share), vs ~$5.7 million a year earlier
- Net loss (TTM): ~$23.5 million
- Cash & equivalents: ~$4.1 million at June 30, 2026 (plus ~$0.2 million restricted); ~$1.2 million raised in September 2026
- Stockholders' equity: ~$3.1 million at June 30, 2026, below NYSE American's $4.0 million standard
- Share structure: 1-for-16 reverse split July 2026, after 1-for-12 in August 2025; large warrant overhang
As of October 2026 (Q2 2026 results, filings through September 2026): A pre-revenue biotech like Calidi cannot be valued on earnings, because there are none; P/E is not meaningful. Investors who study these companies typically weigh the cash runway against the quarterly burn rate, the timing and probability of clinical catalysts (here, a planned CLD-401 first-in-human study in early 2027), and the dilution required to fund it. With a market value near $3 million and cash of a similar size, the market is assigning little value to the pipeline, and the listing-compliance deadline, going-concern doubt and repeated reverse splits mean financing risk dominates any assessment.
Who competes with Calidi Biotherapeutics, Inc. (CLDI)?
Oncolytic-Virus and Virotherapy Companies
Calidi competes in the oncolytic-virus field with companies such as Replimune (REPL), which develops engineered herpes-based oncolytic immunotherapies, and CG Oncology (CGON), focused on a bladder-cancer oncolytic virus. The approved benchmark in the space is Amgen's Imlygic (talimogene laherparepvec). These peers are generally larger and better-capitalized than Calidi, and several have more advanced clinical programs.
Cell-Therapy and Immuno-Oncology Biotechs
Because Calidi uses stem cells to deliver its viruses, it also sits adjacent to the broader cell-therapy and immuno-oncology field, which includes a wide range of clinical-stage companies pursuing engineered cells and tumor-microenvironment approaches. Many of these are also pre-revenue and speculative, but the field as a whole competes for the same scientific talent, trial sites, partnership capital, and investor attention.
Biotech ETFs and Diversified Alternatives
Investors who want exposure to clinical-stage biotech without single-stock risk often use broad ETFs such as the SPDR S&P Biotech ETF (XBI) or the iShares Biotechnology ETF (IBB). Very small micro-caps like CLDI are rarely held in major ETFs, or appear only at tiny weights, so these funds provide diversified biotech exposure rather than direct Calidi exposure. A diversified fund spreads binary trial risk across many companies.
What stocks are similar to Calidi Biotherapeutics, Inc. (CLDI)?
Other names that sit close to CLDI: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. They are useful if you want to spread one thesis across several tickers.
How to invest in Calidi Biotherapeutics, Inc. (CLDI)
There are three common ways to get CLDI exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so CLDI sits alongside other stocks that express the same thesis.
Walnut takes the portfolio route. Describe a thesis where CLDI fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.
New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.
The bottom line on Calidi Biotherapeutics, Inc. (CLDI)
Calidi Biotherapeutics is a pre-revenue cancer-virotherapy company whose value depends on getting CLD-401 into the clinic and on its ability to keep funding operations. It behaves as a binary, highly speculative nano-cap: the shares fell about 95% in 2026 through mid-October, and limited cash, ongoing dilution, a listing-standard deficiency and going-concern doubt make outcomes extremely uncertain.
More on Calidi Biotherapeutics, Inc. (CLDI)
Whether CLDI is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is CLDI a buy or a sell?, and where the stock could go from here in the CLDI stock forecast.
For income investors, whether CLDI pays a dividend and how the payout looks is covered in does CLDI pay a dividend? And to weigh CLDI against a peer, read the full side-by-side comparisons: CLDI vs CG and CLDI vs AMGN.
Wondering how CLDI fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Your questions about Calidi Biotherapeutics, Inc.
Ask Walnut's AI anything about CLDI and see how it fits what you own.
FAQ
What does Calidi Biotherapeutics do?
+
Calidi Biotherapeutics develops cancer therapies built on oncolytic viruses. Its lead effort in 2026 is the RedTail platform, an enveloped virus designed for intravenous delivery to metastatic tumors, whose lead candidate CLD-401 is targeting first patient dosing in early 2027. Earlier programs include CLD-101 (NeuroNova) for brain cancer and CLD-201 (SuperNova), which shield viruses inside stem cells. The company is pre-revenue and has no approved products.
Does CLDI pay a dividend?
+
No. Calidi Biotherapeutics does not pay a dividend. It is a pre-revenue, clinical-stage company that is unprofitable and burns cash, so it directs all available capital toward research and operations rather than returning money to shareholders. Any potential return from CLDI would have to come from share-price appreciation, not income, and the company's limited cash makes a dividend highly unlikely for the foreseeable future.
What are Calidi's main pipeline programs and catalysts?
+
The lead program is now CLD-401 from the RedTail platform, in IND-enabling studies for metastatic lung, head and neck and other solid tumors, with first patient dosing targeted for the first quarter of 2027 after positive FDA pre-IND feedback. CLD-501 adds an in situ T-cell engager. Older programs are CLD-101 (NeuroNova), studied in Phase 1 for high-grade glioma, and CLD-201 (SuperNova), which received FDA IND clearance in April 2025 and Fast Track for soft tissue sarcoma in July 2025. Catalysts include an IND filing, financing news and the NYSE American compliance decision.
Why is CLDI stock so volatile?
+
CLDI is a micro-cap clinical-stage biotech with no revenue, very little cash, and value tied to early trial outcomes, so its price reacts strongly to pipeline news, FDA decisions, and capital raises. Its small market value and low share price mean modest dollar flows can cause large percentage swings. The company has also done a reverse stock split and carries a large warrant overhang, both of which add to share-price instability. In 2026 the shares fell about 95% through October 16, despite a 1-for-16 reverse split in July.
Is Calidi at risk of running out of money or being delisted?
+
Yes, both risks are live. Calidi has reported substantial doubt about its ability to continue as a going concern, had about $4.1 million of cash at June 30, 2026 against quarterly losses near $4 million, and raised only about $1.2 million in September 2026. After reverse splits of 1-for-12 (August 2025) and 1-for-16 (July 2026), it received an NYSE American notice in September 2026 that its $3.1 million of stockholders' equity is below the $4.0 million standard. It must submit a compliance plan by October 21, 2026, and delisting proceedings would start if the plan is not accepted.
Which ETFs or baskets include CLDI?
+
Very small micro-caps like Calidi are rarely included in major biotech ETFs, or appear only at tiny weights, so broad funds such as the SPDR S&P Biotech ETF (XBI) or iShares Biotechnology ETF (IBB) generally do not provide meaningful direct CLDI exposure. On Walnut, you could include CLDI as one holding in a thematic basket, for example alongside other oncolytic-virus or speculative biotech names, while keeping position sizing in mind given its risk.
Is CLDI a good stock?
+
This is descriptive, not advice. The bull case is that Calidi's stem-cell-shielded and systemic virotherapy platforms could reach tumors current therapies cannot, supported by FDA pre-IND alignment on CLD-401 and earlier IND clearance and Fast Track designation for CLD-201. The bear case is that it is a highly speculative, pre-revenue micro-cap with going-concern doubt, very little cash, heavy dilution, two reverse splits, a listing-standard deficiency, and value that hinges on unproven early-stage trials, so a large or total loss is realistic. Whether it fits you depends on your own goals and risk tolerance.
Is CLDI a good stock to buy right now?
+
This is informational, not a recommendation. Calidi is an extremely speculative clinical-stage biotech: it has no revenue, limited cash, substantial doubt about continuing as a going concern, a history of dilution and two reverse stock splits, and an open NYSE American listing deficiency, while its potential rests on early-stage trial outcomes that may take years and could fail. Some investors treat such names as tiny, high-risk positions sized for a possible total loss, while others avoid them entirely. Walnut provides information, not investment advice.
How did Calidi do in its latest quarter?
+
For the second quarter of 2026, Calidi reported a net loss of $4.2 million, or $2.94 per share, narrower than $5.7 million a year earlier, as general and administrative costs fell 48% to $1.6 million while research spending held at $2.6 million. Cash was about $4.1 million at June 30, 2026. The company also reported positive FDA pre-IND feedback on CLD-401.
How has CLDI stock performed in 2026?
+
Very poorly. As of October 16, 2026, CLDI closed at about $0.86, down roughly 95% year to date and about 97% over the past year, near the bottom of a split-adjusted 52-week range of about $0.82 to $27.04, leaving a market value near $3 million. Past performance does not predict future returns, and Walnut provides information, not investment advice.
Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with Calidi Biotherapeutics, Inc.'s investor relations page or your broker before making investment decisions.